Background: Small round blue cell tumors or more commonly called small round cell tumors (SRCTs) are undifferentiated neoplasms, sharing an overlapping morphological pattern of small round blue cells. Diagnosing these tumors represents a complex challenge for cytopathologists and for general surgical pathologist alike. This stems from the fact that these tumors share not only similar morphological features, but also some immunophenotypic characteristics, thus requiring a broad panel of antibodies, which might not be included in the most basic immunohistochemistry panels, used in the routine work of most pathology laboratories. Furthermore, one should note that the diagnosis, prognosis, and/or therapeutic decision are often dependent on the knowledge of the existence of specific molecular alterations, which requires access to sophisticated molecular ancillary techniques. Cytological diagnosis of SRCT should be systematized. A thorough understanding of the morphological pattern of these tumors, the small details they entail, the background and cellular patterns, and the nuclear and cytoplasmic peculiarities, may hint to the most probable diagnosis. Minor clues, such as the presence of a fibrillar background, the presence of rosettes or a specific “salt and pepper” chromatin, are important clues toward a probable diagnosis of a neuroblastoma, or the presence of a tigroid background is a characteristic of rhabdomyosarcoma and the Ewing family tumors. However, in poorly differentiated tumors, morphology alone will not suffice, making it essential for the access to complementary diagnostic techniques in order to reach the final diagnosis. Summary and Key Messages: The cytological diagnosis and treatment of SRCTs require an experienced, well-articulated, proficient teamwork, and sophisticated complementary diagnostic techniques, only available in centers of reference.

1.
Klijanienko
J
,
Pohar Marinšek
Ž
,
Domanski
HA
, editors.
Small volume biopsy in pediatric tumors
.
Springer International Publishing
;
2018
.
2.
Siegel
R
,
Naishadham
D
,
Jemal
A
.
Cancer statistics for Hispanics/Latinos, 2012
.
CA Cancer J Clin
.
2012
;
62
(
1
):
283
98
. .
3.
Ries
LAG
.
Cancer incidence and survival among children and adolescents: United States SEER program, 1975-1995
.
Natl Cancer Inst
.
1999
.
4.
Steliarova-Foucher
E
,
Stiller
C
,
Kaatsch
P
,
Berrino
F
,
Coebergh
JW
,
Lacour
B
,
Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study
.
Lancet
.
2004
;
364
(
9451
):
2097
105
. .
5.
Golden
CB
,
Feusner
JH
.
Malignant abdominal masses in children: quick guide to evaluation and diagnosis
.
Pediatr Clin North Am
.
2002
;
49
(
6
):
1369
viii
. .
6.
Temes
R
,
Allen
N
,
Chavez
T
,
Crowell
R
,
Key
C
,
Wernly
J
.
Primary mediastinal malignancies in children: report of 22 patients and comparison to 197 adults
.
Oncologist
.
2000
;
5
(
3
):
179
84
. .
7.
Brioude
F
,
Lacoste
A
,
Netchine
I
,
Vazquez
MP
,
Auber
F
,
Audry
G
,
Beckwith-wiedemann syndrome: growth pattern and tumor risk according to molecular mechanism, and guidelines for tumor surveillance
.
Horm Res Paediatr
.
2013
;
80
(
6
):
457
65
. .
8.
Robertson
JC
,
Jorcyk
CL
,
Oxford
JT
.
DICER1 syndrome: DICER1 mutations in rare cancers
.
Cancers
.
2018
;
10
(
5
):
143
. .
9.
Barroca
H
,
Marques
C
,
Candeias
J
.
Fine needle aspiration cytology diagnosis, flow cytometry immunophenotyping and histology in clinically suspected lymphoproliferative disorder: a comparative study
.
Acta Cytol
.
2008 Mar–Apr
;
52
(
2
):
124
32
. .
10.
Schmitt
FC
,
Longatto-Filho
A
,
Valent
A
,
Vielh
P
.
Molecular techniques in cytopathology practice
.
J Clin Pathol
.
2007
;
61
(
3
):
258
67
. .
11.
Das
K
,
Mirani
N
,
Hameed
M
,
Pliner
L
,
Aisner
SC
.
Fine-needle aspiration cytology of alveolar rhabdomyosarcoma utilizing ThinPrep® liquid-based sample and cytospin preparations: a case confirmed by FKHR break apart rearrangement by FISH probe
.
Diagn Cytopathol
.
2006
;
34
(
10
):
704
6
.
12.
Bibbo
M
.
How technology is reshaping the practice of nongynecologic cytology: frontiers of cytology symposium
.
Acta Cytol
.
2007 Mar–Apr
;
51
(
2
):
123
52
. .
13.
Klijanienko
J
,
Couturier
J
,
Bourdeaut
F
,
Fréneaux
P
,
Ballet
S
,
Brisse
H
,
Fine-needle aspiration as a diagnostic technique in 50 cases of primary Ewing sarcoma/peripheral neuroectodermal tumor. Institut Curie’s experience
.
Diagn Cytopathol
.
2012
;
40
(
1
):
19
25
.
14.
Thomson
TA
,
Klijanienko
J
,
Couturier
J
,
Brisse
H
,
Pierron
G
,
Freneaux
P
,
Fine-needle aspiration of renal and extrarenal rhabdoid tumors: the experience of the Institut Curie regarding 20 tumors in 13 patients
.
Cancer Cytopathol
.
2011
;
119
(
1
):
49
57
. .
15.
Fine needle aspiration cytology: diagnostic principles and dilemmas
.
Germany
:
Springer-Verlag Berlin
;
2006
.
16.
Rau
AR
,
Kini
H
,
Verghese
R
.
Tigroid background in fine-needle aspiration cytology of clear cell sarcoma
.
Diagn Cytopathol
.
2006
;
34
(
5
):
355
7
. .
17.
Miralles
TG
,
Gosalbez
F
,
Menéndez
P
,
Astudillo
A
,
Torre
C
,
Buesa
J
.
Fine needle aspiration cytology of soft-tissue lesions
.
Acta Cytol
.
1986
;
30
(
6
):
671
8
.
18.
Bahrami
A
,
Gown
AM
,
Baird
GS
,
Hicks
MJ
,
Folpe
AL
.
Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall
.
Mod Pathol
.
2008
;
21
(
7
):
795
806
. .
19.
Wiles
AB
,
Karrs
JX
,
Pitt
S
,
Almenara
J
,
Powers
CN
,
Smith
SC
.
GATA3 is a reliable marker for neuroblastoma in limited samples, including FNA Cell Blocks, core biopsies, and touch imprints: GATA3 as a marker for neuroblastoma
.
Cancer Cytopathology
.
2017
;
125
(
12
):
940
6
.
20.
Klijanienko
J
,
Caly
M
,
Frénaux
P
,
Klos
J
.
GATA3 differential expression in neuroblastoma and nephroblastoma: correspondence
.
Cancer Cytopathology
.
2018
;
126
(
3
):
215
6
.
21.
Kumar
S
,
Perlman
E
,
Harris
CA
,
Raffeld
M
,
Tsokos
M
.
Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues
.
Mod Pathol
.
2000
;
13
(
9
):
988
93
. .
22.
Cessna
MH
,
Zhou
H
,
Perkins
SL
,
Tripp
SR
,
Layfield
L
,
Daines
C
,
Are myogenin and MyoD1 expression specific for rhabdomyosarcoma? a study of 150 cases, with emphasis on spindle cell mimics
.
Am J Surg Pathol
.
2001
;
25
(
9
):
1150
7
. .
23.
Liu
Q
,
Ohshima
K
,
Sumie
A
,
Suzushima
H
,
Iwasaki
H
,
Kikuchi
M
.
Nasal CD56 positive small round cell tumors. Differential diagnosis of hematological, neurogenic, and myogenic neoplasms
.
Virchows Arch
.
2001
;
438
(
3
):
271
9
. .
24.
6–Immunohistochemistry for analysis of soft tissue tumors: 73.
25.
Bellizzi
AM
.
An algorithmic immunohistochemical approach to define tumor type and assign site of origin
.
Adv Anat Pathol
.
2020
;
27
(
3
):
114
63
. .
26.
Sebire
NJ
,
Gibson
S
,
Rampling
D
,
Williams
S
,
Malone
M
,
Ramsay
AD
.
Immunohistochemical findings in embryonal small round cell tumors with molecular diagnostic confirmation
.
Appl Immunohistochem Mol Morphol
.
2005
;
13
(
1
):
1
5
. .
27.
Argani
P
,
Kao
YC
,
Zhang
L
,
Bacchi
C
,
Matoso
A
,
Alaggio
R
,
Primary renal sarcomas with BCOR-CCNB3 gene fusion: a report of 2 cases showing histologic overlap with clear cell sarcoma of kidney, suggesting further link between BCOR-related sarcomas of the kidney and soft tissues
.
Am J Surg Pathol
.
2017
;
41
(
12
):
1702
12
. .
28.
Kao
YC
,
Sung
YS
,
Zhang
L
,
Huang
SC
,
Argani
P
,
Chung
CT
,
Recurrent BCOR internal tandem duplication and YWHAE-NUTM2B fusions in soft tissue undifferentiated round cell sarcoma of infancy: overlapping genetic features with clear cell sarcoma of kidney
.
Am J Surg Pathol
.
2016
;
40
(
8
):
1009
20
. .
29.
Kosemehmetoglu
K
,
Vrana
JA
,
Folpe
AL
.
TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms
.
Mod Pathol
.
2009
;
22
(
7
):
872
8
. .
30.
Kenny
C
,
Bausenwein
S
,
Lazaro
A
,
Furtwängler
R
,
Gooskens
SLM
,
van den Heuvel Eibrink
M
,
Mutually exclusive BCOR internal tandem duplications and YWHAE-NUTM2 fusions in clear cell sarcoma of kidney: not the full story: BCOR and YWHAE-NUTM2 changes in clear cell sarcoma of kidney
.
J Pathol
.
2016
;
238
(
5
):
617
20
.
31.
Antonescu
CR
,
Zhang
L
,
Chang
N
,
Pawel
BR
,
Travis
W
,
Katabi
N
,
EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. a molecular analysis of 66 cases, including soft tissue, bone and visceral lesions, showing common involvement of the EWSR1 gene
.
Genes Chromosomes Cancer
.
2010
;
49
(
12
):
1114
24
.
32.
Nagy
A
,
Somers
GR
.
Round cell sarcomas: newcomers and diagnostic approaches
.
Surg Pathol Clin
.
2020
;
13
(
4
):
763
82
. .
33.
Shern
JF
,
Chen
L
,
Chmielecki
J
,
Wei
JS
,
Patidar
R
,
Rosenberg
M
,
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors
.
Cancer Discov
.
2014
;
4
(
2
):
216
31
. .
34.
Missiaglia
E
,
Williamson
D
,
Chisholm
J
,
Wirapati
P
,
Pierron
G
,
Petel
F
,
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification
.
J Clin Oncol
.
2012
;
30
(
14
):
1670
7
. .
35.
Leiner
J
,
Le Loarer
F
.
The current landscape of rhabdomyosarcomas: an update
.
Virchows Arch
.
2020
;
476
(
1
):
97
108
. .
36.
Spitz
R
,
Hero
B
,
Skowron
M
,
Ernestus
K
,
Berthold
F
.
MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification
.
Eur J Cancer
.
2004
;
40
(
18
):
2753
9
. .
37.
Wang
LL
,
Suganunma
R
,
Ikegaki
N
,
Tang
X
,
Naranjo
A
,
McGrady
P
,
Neuroblastoma: undifferentiated subtype, prognostic significance of prominent nucleolar formation and MYC/MYCN protein expression: a report from the children’s oncology group
.
Cancer
.
2013
;
119
(
20
):
3718
26
.
38.
Wang
LL
,
Teshiba
R
,
Ikegaki
N
,
Tang
XX
,
Naranjo
A
,
London
WB
,
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study
.
Br J Cancer
.
2015
;
113
(
1
):
57
63
.
39.
Mossé
YP
,
Laudenslager
M
,
Longo
L
,
Cole
KA
,
Wood
A
,
Attiyeh
EF
,
Identification of ALK as a major familial neuroblastoma predisposition gene
.
Nature
.
2008
;
455
(
7215
):
930
5
. .
40.
Bresler
SC
,
Weiser
DA
,
Huwe
PJ
,
Park
JH
,
Krytska
K
,
Ryles
H
,
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma
.
Cancer Cell
.
2014
;
26
(
5
):
682
94
. .
41.
Ladanyi
M
,
Antonescu
CR
,
Leung
DH
,
Woodruff
JM
,
Kawai
A
,
Healey
JH
,
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients
.
Cancer Res
.
2002
;
62
(
1
):
135
40
.
42.
Wang
L
,
Bhargava
R
,
Zheng
T
,
Wexler
L
,
Collins
MH
,
Roulston
D
,
Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions
.
J Mol Diagn
.
2007
;
9
(
4
):
498
509
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.